Bicara Therapeutics (BCAX) Operating Leases (2023 - 2026)

Bicara Therapeutics (BCAX) posted quarterly Operating Leases of $301000.0 for Q1 2026, down 49.24% quarter-over-quarter from $593000.0 in Q4 2025.

Bicara Therapeutics (BCAX) Operating Leases (2023 - 2026) Analysis & Trends

Bicara Therapeutics' Operating Leases history runs 4 years deep, the most recent figure standing at $301000.0 for Q1 2026.

In Q1 2026, Operating Leases changed N/A year-over-year to $301000.0; the TTM figure through Mar 2026 stood at $301000.0 (changed N/A YoY), while the FY2025 annual figure was $593000.0, up 352.67% from the prior year.
Operating Leases for Q1 2026 stood at $301000.0, down from $593000.0 in the prior quarter.
The five-year high for Operating Leases was $1.2 million in Q2 2025, with the low at $131000.0 in Q4 2024.
The 4-year median for Operating Leases is $372000.0 (2023), against an average of $511142.9.
The sharpest annual moves came in 2024 and 2025: Operating Leases plunged 64.78% in 2024, then surged 542.34% in 2025.
Bicara Therapeutics' Operating Leases stood at $372000.0 in 2023, then slumped by 64.78% to $131000.0 in 2024, then soared by 352.67% to $593000.0 in 2025, then tumbled by 49.24% to $301000.0 in 2026.
Business Quant data shows BCAX's Operating Leases at $301000.0 in Q1 2026, $593000.0 in Q4 2025, and $880000.0 in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Bicara Therapeutics	1.60 Bn	1.60 Bn	-

Download Data